The Effect of the Menstrual Cycle on Inflammatory Bowel Disease: A Prospective Study by 源��썝�샇 et al.
ORiginal Article
Gut and Liver, Vol. 7, No. 1, January 2013, pp. 51-57
The Effect of the Menstrual Cycle on Inflammatory Bowel Disease: A 
Prospective Study
Sun Min Lim*, Chung Mo Nam†, Youn Nam Kim†, Sin Ae Lee‡, Eun Hye Kim*, Sung Pil Hong*,§, Tae Il Kim*,§, Won Ho 
Kim*,§,∥, and Jae Hee Cheon*,§,∥
Departments of *Internal Medicine, †Biostatistics, Yonsei University College of Medicine, ‡Department of Nursing, Yonsei University College of 
Nursing, §Yonsei Institute of Gastroenterology, and ∥Brain Korea 21 Project for Medical Science, Yonsei University College of Medicine, Seoul, 
Korea
Background/Aims: The symptoms of inflammatory bowel 
disease (IBD) fluctuate considerably over time. However, it 
has not been determined whether these symptoms are af-
fected by the menstrual cycle in female IBD patients. This 
study analyzed the effects of the menstrual cycle on IBD 
symptom variation. Methods: This was a prospective study of 
91 study subjects (47 IBD patients and 44 healthy controls) 
who reported daily symptoms and signs throughout their 
menstrual cycles. Results: IBD patients had significantly 
more frequent gastrointestinal symptoms, such as nausea 
(30% vs 7%, p=0.006), flatulence (53% vs 22%, p=0.003), 
and abdominal pain as compared to controls (68% vs 38%, 
p=0.006). The IBD patients also experienced more frequent 
systemic premenstrual symptoms than the controls (79% vs 
50%, p=0.003). More severe abdominal pain (p=0.002) and 
lower mean general condition scores (p=0.001) were noted 
during the menstrual phase as compared to the pre- or post-
menstrual phase in both groups. IBD patients experienced 
more frequent premenstrual gastrointestinal symptoms than 
controls, but their IBD symptoms did not change significantly 
during the menstrual cycle. Conclusions: Knowledge of the 
cyclic alterations in gastrointestinal and systemic symptoms 
may be helpful in determining the true exacerbation of dis-
ease in female IBD patients. (Gut Liver 2013;7:51-57)
Key Words: Inflammatory bowel diseases; Menstrual cycle; 
Women
INTRODUCTION
Inflammatory bowel disease (IBD) is a chronic recurrent 
Correspondence to: Jae Hee Cheon
Division of Gastroenterology, Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul 120-
749, Korea
Tel: +82-2-2228-1990, Fax: +82-2-393-6884, E-mail: geniushee@yuhs.ac
Received on January 5, 2012. Revised on April 4, 2012. Accepted on May 5, 2012.
pISSN 1976-2283  eISSN 2005-1212  http://dx.doi.org/10.5009/gnl.2013.7.1.51
 This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0) 
which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
inflammatory condition of the gut with unknown etiology. 
Patients with IBD have various presentations such as frequent 
loose stools with abdominal pain, with or without gross, bloody 
stools, tenesmus, constipation, fatigue, and weight loss. These 
symptoms fluctuate considerably over time. Therefore, treatment 
of IBD consists mainly of interpreting and relieving signs and 
symptoms.
Many women experience changing gastrointestinal (GI) 
symptoms caused by hormonal changes related to their men-
strual cycle. In clinical practice, many female patients with IBD 
also report changes in their bowel patterns in relation to their 
menstrual cycle. Previous studies have revealed that GI symp-
toms become more prominent in IBD patients during menstrual 
periods, probably due to changing levels of prostaglandins.1-4 
The exact mechanisms underlying the fluctuation in symptoms 
during the menstrual cycle in relation to ovarian hormones 
currently remain unclear. Chang et al.5 reported that 40% of fe-
male IBD patients experienced fluctuations in symptoms during 
menstruation. Moreover, IBD patients are more likely to report 
changes in bowel habits, with the recurrence of diarrhea being 
more common than constipation.6 It remains to be determined, 
however, whether symptoms specific to IBD patients such as 
nocturnal diarrhea, hematochezia, or fecal incontinence also 
fluctuate during the menstrual cycle.
To date, only a few studies have investigated the relationship 
between the menstrual cycle and bowel symptom changes in 
IBD, most of which have limitations such as retrospective study 
design or lack of IBD-specific symptom evaluation. This is the 
first prospective study to report on this relationship in patients 
with IBD. Herein, we evaluated changes and patterns of bowel 
symptoms during menstrual cycles as reported in a daily di-
52  Gut and Liver, Vol. 7, No. 1, January 2013
ary. This reporting method was employed in order to minimize 
the possible gap between symptoms reported subjectively by 
patients and those objectively assessed by doctors.7,8 We also 
investigated whether IBD-specific symptoms along with non-
specific GI symptoms fluctuate during different phases of the 
menstrual cycle.
MATERIALS AND METHODS
1. Subjects
A total of 47 IBD patients (27 with ulcerative colitis [UC], 13 
with Crohn’s disease [CD], and seven with intestinal Beçhet’s 
disease [BD], who were regularly followed at the GI outpatient 
clinic at Severance Hospital, Yonsei University College of Medi-
cine, and 44 healthy women as controls participated in the 
study. Documented IBD patients were recruited for the study 
during outpatient clinic visits and each was asked to complete 
a daily symptom diary for one menstrual cycle. IBD diagnosis 
and disease activity were defined by clinical, radiographic, en-
doscopic, and histological changes.9-12 Only patients who were 
in clinical remission status or had mild disease severity during 
the study dates were included. Patients with moderate or severe 
disease activity were excluded in order to avoid overlooking 
relatively small menstrual symptom variations. Patients with 
combined malignant diseases, kidney diseases, cardiovascular 
diseases, psychiatric illness, or a history of abdominal surgery 
were also excluded.
2. Data collection
A common questionnaire was given to each subject. The con-
tents addressed smoking, alcohol consumption, pregnancy his-
tory, menstrual history, and medications used.
Participants were also asked about GI symptoms and patterns 
according to the phase of the menstrual cycle. We defined the 
premenstrual period as ‘7 days’ before the start of menses. The 
systemic premenstrual syndrome (PMS) and the GI symptoms 
were reported by the respondents. Systemic PMS was defined as 
a series of symptoms including headache, anxiety, depression, 
mastalgia, urinary frequency, and edema before starting men-
struation. GI symptoms associated with PMS included diarrhea, 
constipation, nausea, abdominal pain, flatulence, straining, and 
tenesmus.13 Finally, a separate questionnaire was given to each 
IBD patient and control for which they were required to report 
daily symptoms and signs throughout the menstrual cycle: 
number of stools (per day), number of loose stools (per day), ab-
dominal pain score (based on a scale of 0 to 3, where: 0, none; 
1, mild; 2, moderate; 3, severe), general condition score (based 
on a scale of 0 to 5, where: 0, perfect; 1, very good; 2, good; 3, 
average; 4, poor; 5, terrible), nocturnal diarrhea (number, %), 
hematochezia (number, %), fecal incontinence (number, %), and 
the need for anti-diarrheal agents (number, %). Since the length 
of a menstrual cycle varies from month to month and from 
women to women, we assumed the cycle length to be 28 days, 
each cycle including a premenstrual (7 days before the start of 
menses), menstrual, and postmenstrual (7 days after the end of 
menses) phase. The completed questionnaire was collected when 
the patients visited the outpatient clinic for a routine follow-
up. The questionnaire and study protocol were approved by the 
Severance Hospital Institutional Review Board. This study pro-
tocol was also designed in accordance with the ethical guide-
lines of the Declaration of Helsinki. Written informed consent 
was obtained from all participants or their guardians before 
they were enrolled in the study.
3. Sample size and statistical analysis
Sample sizes of 47 in the disease group and 44 in the control 
group achieved a power of 87% for detecting a difference in 
PMS proportion of 0.3. The PMS proportion was assumed to be 
0.8 in the disease group and 0.5 in the control group. A two-
sided independent t-test with pooled variance was used, and 
the significance level of the test was set at 0.05. Data are ex-
pressed as means±standard deviations (SDs) or frequencies and 
percentages. The two-sided independent t-test and chi-square 
test were used to test for differences in the mean values of con-
tinuous measures and frequency rates between the two groups, 
respectively. We used generalized estimating equations (GEE) to 
analyze day-to-day menstrual symptom data between the two 
groups. This approach allowed us to consider individual correla-
tions in the data by way of a working covariance matrix. Daily 
data, such as the number of stools and the number of loose 
stools, were assumed to follow the Poisson distribution. Because 
the distribution of the daily scaled data including abdominal 
pain, general condition, and abdominal tenderness were posi-
tively skewed, these variables were log transformed in the GEE 
analysis. However, they are expressed as nontransformed scales 
with mean±SDs for the sake of clarity. The GEE model included 
main effect terms for group and menstrual phases and an in-
teraction term between the groups and menstrual phase. The 
interaction was tested in order to detect whether there was a 
differential group effect following the menstrual phase. Z-score 
statistics based on GEE empirical standard errors were used to 
test the main effect and interaction terms. All tests were judged 
to be significant at a 5% significance level.
RESULTS
1. Baseline characteristics of the IBD patient and control 
groups
Table 1 shows the baseline characteristics of the disease and 
control groups. There were 47 IBD patients and 44 controls. The 
mean age was 35±8 years for the IBD group and 33±3 years 
for the control group. There were no significant differences in 
height, weight, or BMI between the two groups. There were 
more parous women (36% vs 25%) and more current smokers 
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(4% vs 0%) in the disease group. The mean length of the men-
strual cycle (32.17±3.53 days vs 32.20±6.20 days) and the mean 
menstrual period duration (5.22±1.18 days vs 5.22±1.20 days) 
did not differ between the two groups. Among the patients, 62% 
were on 5-aminosalicylic acids or sulfasalazine, 30% were on 
azathioprine/6-mercaptopurine, 8% were on systemic steroids, 
and 4% were on infliximab therapy. Thirty-eight patients (80%) 
were in clinical remission; the rest showed mild disease severity 
at the time of study. Premenstrual symptoms were significantly 
more frequent in the IBD patients than in the controls (79% vs 
50%, p=0.003), as shown in Table 2.
We compared the subjective symptoms reported by each 
subject during menstruation. This questionnaire was not neces-
sarily completed during the time of menses. For GI symptoms, 
nausea (30% vs 7%, p=0.006), abdominal discomfort/pain (68% 
vs 38%, p=0.006), flatulence (53% vs 22%, p=0.003), and te-
nesmus (25% vs 4%, p=0.007) were reported at a significantly 
higher frequency in the patient group. Diarrhea, constipation 
and straining were not significantly different between the two 
groups. The systemic premenstrual symptoms that were evaluat-
ed included headache, anxiety, depression, acne, edema, urinary 
frequency, and mastalgia. There were no significant differences 
in these symptoms as a whole between the two groups. While 
the IBD group reported more headaches (30% vs 14%), anxiety 
(34% vs 25%), depression (19% vs 14%) and mastalgia (34% 
vs. 34%), the control group reported more acne (21% vs. 25%), 
edema (15% vs. 29%), and urinary frequency (13% vs. 16%). 
Table 1. Baseline Characteristics of Women with Inflammatory Bowel 
Disease and Controls
Patients 
(n=47)
Controls 
(n=44)
p-value
Age, yr 35±8 33±3 0.230
Height, cm 159.1±5.44 161.6±5.03 0.402
Weight, kg 51.62±6.89 53.25±4.98 0.127
BMI, kg/m2 20.41±2.57 20.37±1.67 0.932
Parous 17 (36) 11 (25) 0.012
Current smoker 2 (4) 0 (0) 0.175
Length of menstrual cycle 32.17±3.53 32.20±6.20 0.281
Menstruation duration, day 5.25±1.18 5.22±1.20 0.996
Subtype of disease -
   Ulcerative colitis 27 (57.4) -
   Crohn’s disease 13 (27.7) -
   Intestinal Behcet’s disease 7 (14.9) -
Medications used -
   5-aminosalicylic acids 29 (62) -
   Azathioprine/6-MP 14 (30) -
   Systemic corticosteroids 4 (8) -
   Infliximab 2 (4) -
Disease activity -
   Complete remission 38 (80) -
   Mild 9 (20) -
Data are presented as mean±SD or number (%).
Table 2. Comparison of Symptoms between Women with Inflamma-
tory Bowel Disease and Controls
Symptom
Patients 
(n=47)
Controls 
(n=44)
p-value
Premenstrual symptoms 37 (79) 22 (50) 0.003  
Nongastrointestinal symptoms
   Headache 14 (30) 6 (14) 0.077 
   Anxiety 16 (34) 11 (25) 0.364 
   Depression 9 (19) 6 (14) 0.575 
   Acne 10 (21) 11 (25) 0.806 
   Edema 7 (15) 13 (30) 0.132 
   Urinary frequency 6 (13) 7 (16) 0.771 
   Mastalgia 16 (34) 15 (34) 0.943 
Gastrointestinal symptoms
   Diarrhea 12 (26) 9 (20) 0.622 
   Constipation 4 (8) 11 (25) 0.050 
   Nausea 14 (30) 3 (7) 0.006 
   Abdominal discomfort/pain 32 (68) 17 (39) 0.006 
   Flatulence 25 (53) 10 (23) 0.003 
   Straining 4 (9) 2 (5) 0.677 
   Tenesmus 12 (25) 2 (5) 0.007 
Data are presented as number (%).
Table 3. Mean Gastrointestinal Symptom Severity during Phases of the Menstrual Cycle in Inflammatory Bowel Disease Patients and Healthy 
Controls
Premenstrual Menstrual Postmenstrual p-value
Patient Control Patient Control Patient Control Group Phase
Group×phase 
interaction
No. of stools, n/day 3.10±2.11 1.00±0.00 3.49±2.19 1.06±1.17 2.69±2.03 1.06±0.37 <0.001 0.052 0.843
No. of loose stools, n/day 2.19±2.23 0.20±0.46 2.36±2.17 0.47±0.84 1.94±1.97 0.07±0.25 <0.001 0.167 0.122
Mean abdominal pain (scale of 0-3) 0.72±0.81 0.42±0.75 0.89±0.89 0.87±0.94 0.47±0.61 0.11±0.38 0.001 0.002 0.227
Mean general condition (scale of 0-5) 2.19±1.31 1.89±1.09 2.50±1.46 2.62±1.25 2.11±1.19 1.51±0.87 0.105 0.001 0.008
Data are presented as mean±SD. 
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2. Relationships between menstrual cycle and IBD symp-
toms
We evaluated the relationships between menstrual cycle 
and GI symptoms. Table 3 compares the symptoms among the 
three phases of the menstrual cycle: premenstrual, menstrual, 
and postmenstrual. The patient group experienced a signifi-
cantly higher number of stools (p<0.001), higher number of 
loose stools (p<0.001), and more severe mean abdominal pain 
(p=0.001) than the controls in all phases. We then compared the 
fluctuation in symptoms according to menstrual phase. Both 
patients and controls reported more symptoms during the men-
strual phase than the premenstrual or postmenstrual phase.
Both patients and controls reported significantly more se-
vere abdominal pain (p=0.002) and poorer general condition 
(p=0.001) scores during the menstrual phase than during the 
pre- or postmenstrual phases. However, the number of stools 
and loose stools did not change significantly during the differ-
ent phases of menstruation. Fig. 1 shows the comparison of dai-
ly trends in regards to GI symptoms (number of stools, number 
of loose stools, mean abdominal pain score, and mean general 
condition score).
The IBD-specific symptoms such as nocturnal diarrhea, he-
matochezia, fecal incontinence, and the need for anti-diarrheal 
agents were mainly limited to the patient group. We therefore 
evaluated whether these IBD symptoms were aggravated during 
the menstrual phase as shown in Table 4. Nocturnal diarrhea 
Fig. 1. Gastrointestinal symptom scales throughout the menstrual cycle for women with inflammatory bowel disease and women in the control 
group. (A) Number of stools. (B) Mean abdominal pain. (C) Mean general condition. (D) Number of loose stools.
Table 4. Mean Specific Inflammatory Bowel Disease (IBD)-Related 
Symptom Frequency of IBD Patients According to Phases of the 
Menstrual Cycle
Premen-
strual
Menstrual
Postmen-
strual
p-value
Nocturnal diarrhea 11 (31) 12 (33) 5 (14) 0.263
Hematochezia 3 (8) 4 (11) 3 (8) 0.386
Fecal incontinence 10 (28) 6 (17) 6 (17) 0.508
Need for antidiarrheal 
agents
3 (8) 1 (3) 2 (6) 0.370
Data are presented as number (%).
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and hematochezia were most commonly reported during the 
menstrual phase, but fecal incontinence and the need for anti-
diarrheal agents were more common during the premenstrual 
phase. However, there was no significant difference in these 
symptoms between the three phases, and they did not worsen at 
the time of menses.
DISCUSSION
We investigated whether IBD-specific symptoms along with 
nonspecific GI symptoms fluctuated during different phases of 
the menstrual cycle in IBD patients compared to healthy con-
trols. The strengths of our study include its prospective design 
in which subjects were asked to report their symptoms and 
bowel habits daily. This design minimizes possible recall bias 
and reduces over- or underestimation of symptoms. Moreover, 
the statistical analysis used in this study allowed us to precisely 
compare trends in individual results both phase-wise and group-
wise.
In this study, we found that the IBD patients experienced 
more frequent premenstrual GI symptoms than the controls, but 
systemic premenstrual symptoms did not differ significantly 
between the two groups. We also found that the bowel habits 
of both groups changed during the different phases of the men-
strual cycle, although significant differences were not found. 
More severe mean abdominal pain and aggravated mean gen-
eral condition scores were observed in both groups during the 
menstrual phase, compared to other phases.
Finally, the patient group experienced a significantly higher 
number of stools, a higher number of loose stools, and more 
severe mean abdominal pain throughout the menstrual cycle. 
However, specific IBD-related symptoms such as nocturnal diar-
rhea, hematochezia, fecal incontinence, and the need for an-
tidiarrheal agents did not change according to menstrual phase 
in the IBD patients. The menstrual cycle is often overlooked, 
although it can be a confounding variable in disease activity 
in women with IBD. As the severity of IBD is evaluated using 
symptom-based criteria, physicians should be aware that wors-
ening symptoms may not be due to disease exacerbation, but 
may rather be due to menstruation. This implies that menstrual 
cycles should be considered by physicians in clinical settings.
Premenstrual syndrome (PMS) is characterized as the cyclic 
recurrence of symptoms during the luteal phase of the men-
strual cycle. The PMS diagnostic criteria were developed by the 
University of California at San Diego and the National Institute 
of Mental Health, and emphasize the periodicity and severity 
of symptoms. The etiology of PMS is multifactorial, and it is 
related to ovulating hormones secreted during the menstrual 
cycle. Previous studies have reported on the symptomatology 
of IBD or irritable bowel syndrome (IBS) in association with the 
menstrual cycle, although the mechanisms underlying the effect 
of these hormones on symptoms have not yet been elucidated. 
It was previously reported that 67% of healthy women experi-
enced irritability, 35% depression, 19% diarrhea, and 13% con-
stipation during the premenstrual phase.13-15 Heitkemper et al.1 
evaluated symptoms across the menstrual cycle in women with 
IBS. The ovulatory cycle was confirmed by measuring luteiniz-
ing hormone surge and progesterone levels in each subject. They 
compared the frequency of bowel symptoms such as diarrhea, 
constipation, and alternations in symptoms across the menstrual 
cycle and concluded that the IBS patients reported more GI and 
somatic symptoms than the controls.1 Unfortunately, the phe-
nomenon of symptom fluctuation during the menstrual cycle 
in relation to ovarian hormones was not clearly explained. A 
study by Kane et al.2 found that PMS and menstrual symptoms 
are reported more frequently by patients with IBS and IBD than 
by controls, and IBS and IBD patients are more likely to report 
a “cyclical” pattern to their bowel habits.2 However, their study 
was a retrospective study based on telephone interviews, so 
the subjects may have over reported their symptoms. Parlak et 
al.16 conducted a similar study assessing the pattern of GI and 
psychosomatic symptoms during the menstrual cycle in women 
with IBD. They demonstrated that there is a cyclic pattern in 
defecation during the menstrual phase.16 Their results are in ac-
cordance with those of our study in that the occurrence of GI 
symptoms were higher in IBD patients than in controls. How-
ever, in study of Parlak et al.,16 there was no mention of specific 
IBD symptoms being manifested more frequently in patients. 
Thus, our study is the first to use prospective diary data to as-
sess the effects of the menstrual cycle on IBD symptoms.
The mechanism underlying changes in GI symptoms dur-
ing the menstrual cycle has been linked to gonadal hormones 
such as prostaglandins. Dysmenorrhea is linked to an excess or 
imbalance of prostaglandins and arachidonic acid metabolites. 
Production of the prostaglandin subtype PGE2 in the intestines 
leads to increased contraction of the colonic smooth muscle. 
The higher frequency of defecation during the menstrual phase 
may be caused by an excessive prostaglandin release from the 
uterine cavity.17
Gonadal hormones also influence pain sensitivity via a va-
riety of mediators including serotonin (5-hydroxytryptamine, 
5-HT), which is ubiquitous in the GI tract.18 Borman et al.19 
proposed that serotonin receptors contribute to the putative 
5-HT-induced colonic smooth muscle hypersensitivity associ-
ated with IBS. Estrogen is associated with 5-HT receptors via 
estrogenic pathways, which influence tryptophan hydroxylase, 
the synthetic enzyme for 5-HT. Estrogen is also known to en-
hance serotonergic postsynaptic responsiveness in the central 
nervous system. Therefore, estrogen-serotonin interactions lead 
to increased vulnerability to fluctuating bowel symptoms and 
mood changes during the menstrual cycle. GI symptoms such 
as abdominal pain appear before menstruation when there is a 
rapid decline in estrogen production. This is because estrogen 
alleviates cramps by reducing the manifestation of serotonin re-
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ceptors.20,21 A recent study revealed that estrogen and progester-
one could relieve colon contractility in Sprague-Dawley rats.22 
This phenomenon was evident in our results, which showed that 
both patients and controls experienced more severe abdominal 
pain during the premenstrual and menstrual phases than in the 
postmenstrual phase. However, there is no evidence that ovarian 
hormones influence the disease activity of IBD, as IBD specific 
symptoms did not fluctuate significantly during the menstrual 
cycle in our study. Hormonal analysis with respect to the men-
strual cycle needs further research and investigation.
One limitation of our study is that the symptoms we observed 
were mainly related to UC, but not to CD and BD. Furthermore, 
the results were obtained from the subjective symptom evalua-
tions of each patient, although menstrual periods are affected by 
multiple factors such as stress, exercise, food intake, and medi-
cation. The concomitant use of medications or immunosuppres-
sive agents taken by patients with IBD could overshadow the 
symptoms and thus act as a confounding factor. The issue of 
intra-individual variability is another concern when assessing 
the consistency of symptoms. It may be necessary to use long-
term follow-up questionnaires to examine the manifestations of 
repeating GI and systemic symptoms on an individual basis.
In conclusion, our study highlights the fact that IBD patients 
are more likely to report PMS and GI symptoms than healthy 
women, without exacerbation of disease specific symptoms. 
Physicians should consider a gender-based approach in clinical 
practice, and acknowledge that gender-specific issues such as 
menstruation can influence symptoms and signs throughout the 
menstrual cycle. Lastly, knowledge of cyclic symptom altera-
tions may be helpful in determining the true exacerbation of 
IBD.
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